[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights: On 07/25/2025 Protagonist Therapeutics (PTGX) President & CEO Dr. Dinesh V. Patel sold 10,415 common shares at a weighted-average price of $54.78 (range $54.75-$54.82). The transaction was coded “S” (open-market sale).

Following the sale, Dr. Patel’s direct holding stands at 520,603 shares. The divestiture equals roughly 2.0 % of his post-transaction position, indicating he retains a substantial stake and continued alignment with shareholders.

No derivative securities were involved and the filing contains no other material events or financial data.

Positive

• CEO retains 520,603 shares, demonstrating ongoing ownership alignment despite the recent sale.

Negative

• Insider sale by CEO may be viewed as a modestly bearish sentiment indicator.

Insights

Corporate Governance Analyst

TL;DR: Small open-market sale by PTGX CEO; mildly negative optics but immaterial to control.

The 10,415-share sale represents ≈2 % of Dr. Patel’s holdings and less than 0.2 % of the 52 m share float, so dilution or control concerns are negligible. Nonetheless, insider selling—especially by the CEO—can be perceived as a modest bearish signal, particularly near a 52-week high around $55. The absence of additional context (e.g., tax, diversification) limits interpretation. Overall impact is low; investors should monitor future filings for pattern changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/25/2025		S		10,415	D	$54.78(1)	520,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $54.82. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many PTGX shares did CEO Dinesh Patel sell?

He sold 10,415 common shares on 07/25/2025.

What was the sale price for the PTGX shares?

The weighted-average price was $54.78, with trades between $54.75 and $54.82.

How many PTGX shares does the CEO still own after the sale?

Dr. Patel retains 520,603 shares held directly.

Does the filing report any derivative transactions?

No, Table II shows no derivative securities acquired or disposed.

Is the insider sale significant for PTGX investors?

The sale equals about 2 % of the CEO’s holdings and is unlikely to impact control or valuation materially.